New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
06:33 EDTONCYOncolytics Biotech announces positive data from Resolysin clinical trial
Oncolytics Biotech announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website. The conference is being held from May 30th to June 3rd Chicago, Illinois. The abstract, titled "Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients," contends that intravenous delivery to brain tumors would be easier, cheaper and more acceptable to patients than intralesional administration.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
06:41 EDTONCYOncolytics announces completion of enrollment in Phase II Reolysin study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer. The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario. The study is an open-label, randomized, non-blinded, Phase II clinical study of Reolysin given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients were enrolled in each arm. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.
06:34 EDTONCYOncolytics completes enrollment in Phase II study of Reolysin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use